<DOC>
	<DOC>NCT00091559</DOC>
	<brief_summary>A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher) who have progressive, persistent, or recurrent disease on or following 2 other therapies, one of which must have contained Targretin (bexarotene)or for patients who are not candidates or could not tolerate Targretin therapy.</brief_summary>
	<brief_title>Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients with Cutaneous Tcell Lymphoma (Stage 1B or higher) Age: over 18 years of age Have the ability to swallow capsules. You must be at least 3 weeks from any prior chemotherapy or anticancer therapy treatment and have recovered from any side effects of that treatment. Patients also require adequate heart, liver, and kidney function. Pregnant and nursing women and those with known allergy to the study drug are excluded from this study. Patients are excluded if they are currently receiving chemotherapy, radiation therapy, or other investigational anticancer therapy. Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics or antifungal agents are not permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CTCL</keyword>
</DOC>